Unity Biotechnology, Inc. (UBX)
$1.61
Insights on Unity Biotechnology, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.8% return, outperforming this stock by 82.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.3% return, outperforming this stock by 329.1%
Performance
- $1.59$1.63$1.61
1.51%
Downside
Day's Volatility :2.72%
Upside
1.23%
- $1.46$3.82$1.61
9.32%
Downside
52 Weeks Volatility :61.78%
Upside
57.85%
Returns
| Period | Unity Biotechnology, Inc. | Russel 2000 | Index (Russel 2000) |
|---|---|---|---|
3 Months | -4.17% | 0.0% | 0.0% |
6 Months | -21.46% | 0.0% | 0.0% |
1 Year | -31.2% | 0.5% | 0.5% |
3 Years | -96.76% | -21.1% | -21.1% |
Highlights
Market Capitalization | 24.8M |
Book Value | $1.69 |
Earnings Per Share (EPS) | -2.7 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.3% |
Return On Equity TTM | -94.36% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -35.2M |
EBITDA | -37.3M |
Diluted Eps TTM | -2.7 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.24 |
EPS Estimate Next Year | -2.32 |
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Next Quarter | -0.55 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 272.67%
Technicals Summary
Sell
Neutral
Buy
Unity Biotechnology, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Unity Biotechnology, Inc. | 2.55% | -21.46% | -31.2% | -96.76% | -98.27% |
 Moderna, Inc. | 21.5% | 73.44% | -8.79% | -23.24% | 361.25% |
 Regeneron Pharmaceuticals, Inc. | 1.52% | 14.97% | 25.57% | 98.37% | 178.01% |
 Novo Nordisk A/s | -2.23% | 21.74% | 50.76% | 232.25% | 415.39% |
 Vertex Pharmaceuticals Incorporated | -1.37% | 3.97% | 15.22% | 87.53% | 129.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Unity Biotechnology, Inc. | NA | NA | NA | -2.24 | -0.94 | -0.25 | NA | 1.69 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Unity Biotechnology, Inc. | Buy | $24.8M | -98.27% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
Institutional Holdings
ARCH VENTURE CORP
5.99%Armistice Capital, LLC
4.10%Vanguard Group Inc
3.35%Geode Capital Management, LLC
0.79%Mayo Clinic
0.74%BlackRock Inc
0.67%
Corporate Announcements
Unity Biotechnology, Inc. Earnings
Unity Biotechnology, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Organization | Unity Biotechnology, Inc. |
Employees | 19 |
CEO | Dr. Anirvan Ghosh Ph.D. |
Industry | Health Technology |
